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Abstract
Background: Ovarian cancer is the most fatal of gynaecological malignancies, usually detected at a late stage with
intraperitoneal dissemination. Appropriate preclinical models are needed that recapitulate both the
histopathological and molecular features of human ovarian cancer for drug-efficacy analysis.
Methods: Longitudinal studies comparing cisplatin performance either alone or in a novel cisplatin-based
delivery-system, cucurbit[7]uril-encapsulated cisplatin (cisplatin@CB[7]) were performed on subcutaneous (s.c.)
and intraperitoneal (i.p.) xenografts using the human ovarian cancer cell line A2780 stably expressing the
small GTPase Rab25, which allows A2780 intraperitoneal growth; and luciferase, to allow tumour load
measurement by non-invasive bioluminescent imaging.
Results: Rab25 expression induced cisplatin resistance compared to the parental cell line as assessed by the
MTT assay in vitro. These findings did not translate in vivo, where cisplatin resistance was determined by the
microenvironment. Subcutaneous xenografts of either parental A2780 or cisplatin-resistant Rab25-expressing
A2780 cells presented similar responses to cisplatin treatment. In contrast, increased cisplatin resistance was
only detected in i.p. tumours. Treatment of the cisplatin-resistant i.p. model with the novel cisplatin@CB[7]
delivery system resulted in a substantial reduction of i.p. tumour load and increased necrosis.
Conclusions: Poor clinical performance of novel chemotherapeutics might reflect inappropriate preclinical
models. Here we present an ovarian i.p. model that recapitulates the histopathological and chemoresistant
features of the clinical disease. In addition, we demonstrate that the novel cisplatin-delivery system,
cisplatin@CB[7] may have utility in the treatment of drug-resistant ovarian human cancers.
Background
Ovarian cancer is the most lethal of all gynaecological
cancers, mostly because it is detected at late clinical
stages, when the treatment is less effective [1]. Late stage
ovarian cancer presents with widespread peritoneal dis-
semination and ascites. Treatment usually involves aggres-
sive cytoreductive surgery, and modern combination
chemotherapy (platinum and paclitaxel) or i.p. cisplatin
based-chemotherapy [2–6]. Lack of an adequate screening
test for early disease detection and the rapid progression
to chemoresistance have prevented appreciable improve-
ment in the five year survival rate of patients with ovarian
cancer [7]. Dissemination of single tumour cells into the
peritoneal cavity is the major cause of tumour recurrence
even after complete resection of the primary solid tumour
[8, 9]. Currently, there is no effective treatment for peri-
toneal carcinomatosis [10]. Preclinical models that mimic
the complexity of tumour behaviour and microenviron-
ment in patients are essential for the evaluation of novel
chemotherapeutics. These preclinical models include
models of spontaneous ovarian carcinoma in experimental
animals [11, 12] or genetically modified animals [13, 14].
However, the long latency to tumourigenesis and the
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heterogeneity in the timing of advanced tumour develop-
ment makes the use of these models in preclinical studies
challenging. Ovarian cancer cell lines derived from ascites
or primary ovarian tumours have been used extensively
and can be very effective for studying the processes con-
trolling growth regulation and chemosensitivity [15].
However, most of these studies rely on subcutaneous
xenografts, that do not provide the relevant tumour
microenvironment which that might influence treatment
response [9]. Tumour formation resulting from peritoneal
implantation of human ovarian carcinoma cells holds
promise as pre-clinical models of human ovarian cancer,
as they are relatively rapid to generate and develop in the
relevant microenvironment. Expression of Rab25, a mem-
ber of the Ras superfamily of GTPases, in the ovarian can-
cer cell line A2780, allows these cells to invade and grow
in the peritoneum of mice, resulting in tumour growth ac-
cumulation and death recapitulating the peritoneal dis-
seminated disease in humans [16]. Rab25 was discovered
to be the driving event of the 1q22 genomic amplification
associated with poor disease-free survival rate following
surgical and chemotherapy procedures [16]. Its enforced
expression in ovarian and breast cancer cell lines induced
cell number through reduced apoptosis after multiple
stress conditions, including UV radiation and exposure to
paclitaxel [16]. These results suggest that Rab25 expres-
sion might also influence cisplatin resistance.
In the present study, we have developed a model of peri-
toneal ovarian carcinomatosis in athymic immunodeficient
mice using the A2780 cell line overexpressing Rab25 that
can be monitored longitudinally through by biolumines-
cence. We show that Rab25 expression in this cell line
induces cisplatin resistance in vitro and in vivo, although
the in vivo resistance to treatment is also determined by
the localisation of the tumour. In addition, we confirm in-
creased anti-tumour activity of the novel cisplatin delivery
system Cucurbit[7]uril (cisplatin@CB[7]) compared to free
cisplatin in the i.p. model which exceeded that observed in
the s.c. model. Cucurbit[n]uril is a barrel-shaped molecule,
containing a hydrophobic cavity, formed by the acid cata-
lysed condensation of glycoluril and formaldehyde. Cucur-
bit[n]urils can be synthesised in a variety of sizes (n=5, 6, 7,
8 and 10), and are capable of encapsulating smaller mole-
cules within their cavities. Our results demonstrate that
cisplatin@CB [7] may have utility in the treatment of drug-
resistant ovarian human cancers and warrant further
investigation.
Results
Development of a bioluminescent ovarian cancer model
in athymic mice
To generate an i.p. ovarian cancer model where tumour
burden can be monitored and measured non-invasively,
we developed an A2780-Rab25 stable cell line expressing
the firefly luciferase gene under the control of the ubiqui-
tin C promoter using a lentiviral gene delivery system.
Luciferase-expressing cells injected into the peritoneal
cavity of mice allow their imaging in the living animal
after luciferin injection using the Xenogen IVIS50 system.
Intraperitoneal injection of A2780 cells stably expressing
Rab25 and luciferase resulted in tumour growth accumu-
lation and death of all the animals injected, whereas only
20 % of the animals injected with the parental cell line
expressing empty vector produced disease (Fig. 1a). The
growth of these tumours was followed in longitudinal
studies where bioluminescence quantification of the
tumour burden was performed in real time in a single ani-
mal (Fig. 1a). The tumours localised to the peritoneum,
presenting one or two big tumours invading the intestine,
liver, pancreas and/or stomach (Fig 1b), and several small
tumours spread throughout the peritoneal cavity.
Rab25 expression increases cisplatin resistance in vitro
The A2780 cell line presents high sensitivity towards
cisplatin (IC50 0.1 μM by MTT). Rab25 was discovered in
tumours that did not respond to chemotherapy, impli-
cating Rab25 as a potential oncogene regulating chemo-
resistance. Expression of Rab25 in the A2780 cell line
increased a 2.8 fold cisplatin resistance compared to
vector-only cells as measured by MTT assay (A2780-
Rab25Luc IC50 = 0.555 ± 0.058 μM to A-Luc IC50 =
0.1973 ± 0.0217 μM, Fig. 2b). To investigate if Rab25 ex-
pression could affect the cisplatin sensitivity in vivo, s.c.
xenografts of either the ovarian parental cell line A2780 or
the A2780-Rab25 cell line were compared. Once tumours
were established, the mice were treated with a single dose
at the maximum tolerated dose (MTD) for cisplatin of
6 mg/kg and tumour growth was monitored using caliper
measurements. The Rab25-expressing and the parental
A2780 s.c. xenografts presented a very similar response
to cisplatin, demonstrating that the Rab25 conferred che-
moresistance to cisplatin was lost in vivo (Fig. 2c).
Evaluation of the i.p. model for cisplatin treatment
To investigate whether tumour microenvironment deter-
mines response to cisplatin in ovarian cancer xenografts,
A2780-Rab25 cells were injected into nude mice either
subcutaneously or intraperitoneally. Establishment of the
tumours was very different in each model. One week after
subcutaneous injection of the cells, the tumours were
ready to be monitored by bioluminescence and the mice
were treated at this time with cisplatin at the MTD and
imaged three times during the course of the experiment
(Fig. 3a). Slower development of tumours was observed in
the i.p. model. After i.p. injection of cells, the mice were
imaged once weekly until the appearance of biolumines-
cent signal was detected, and the signal was above 8x105
flux (around three to four weeks; data not shown). At this
Gomez-Roman et al. Journal of Ovarian Research  (2015) 8:62 Page 2 of 10
time, the animals were treated with cisplatin at the MTD,
and imaged three times for the same period as s.c. xeno-
grafts (14 days; Fig. 3b). Both s.c. and i.p. tumours
presented growth delays after cisplatin treatment. While
the rapid growing s.c. xenografts reached only 35 % of the
signal to that of control at day 14, the slow growing i.p.
xenografts reached ~60 % at the same time (Fig. 3). These
results demonstrate that the s.c. xenografts are more
sensitive to cisplatin than the i.p. tumours.
Induction of p53 by cisplatin in the A2780-Rab25 i.p.
xenografts
The increased chemoresistance observed in the i.p. xeno-
grafts could be explained by reduced drug penetrance to
the i.p. tumours. To assess if cisplatin was reaching the i.p.
xenografts, we developed an A2780-Rab25 cell line stably
expressing a luminescent p53-luciferase reporter, contain-
ing the luciferase gene under the control of a p53 regu-
lated promoter. Cisplatin produces DNA adducts [17]
which stabilise and activate p53, inducing the expression
of its downstream targets genes involved in apoptosis
(Zamble, 1998). The A2780-Rab25 cell line expresses
normal p53 that responds to cisplatin treatment (Fig. 3d),
as represented by an increase in full-length p53 as well as
an increase in a p53 splice variant (lower band). Exposure
to different concentrations of cisplatin for 24 hrs induced
a dose–response activity of the p53-driven luciferase
reporter in vitro (Fig. 3e). To analyse if we could monitor
p53 activation in vivo after cisplatin treatment in the i.p.
model, we generated i.p. xenografts with A2780-Rab25
stably expressing the p53-luciferase reporter. Four weeks
after cell injection, mice were treated with cisplatin at the
MTD. An increase in luminescence was observed in the
tumours compared to control (Fig. 3f), confirming that
cisplatin is indeed reaching the i.p. tumours.
Activity of Cisplatin@CB[7] on the A2780-Rab25 i.p. model
The delivery of platinum drugs can be improved through
their encapsulation, by taking advantage of the enhanced
permeability and retention effect and/or protection from
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Fig. 1 A2780 cells expressing Rab25 produce intraperitoneal disease in nude mice. a Nude mice were injected i.p. with 5 × 106 of A2780 or
A2780-Rab25 cells stably expressing luciferase and monitored over time by measuring luciferase expression after s.c. administration of luciferin
(30 mg/ml) using an IVIS-50 imaging system. b H&E images of tumours taken from mice at 28 days after inoculation. T = tumour; Int = intestine
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degradation and deactivation. Cucurbit[7]uril (CB[7]), is a
rigid macrocycle made from the condensation of glycoluril
and formaldehyde [18, 19] and is capable of storing and
releasing small molecules for controlled drug release. En-
capsulation within CB[7] also provides steric hindrance to
degradation by thiol amino acids, peptides and proteins for
both multinuclear and mononuclear platinum drugs [20].
The effect of CB[7] encapsulation on the cytototoxicity
of cisplatin was evaluated in vitro in the human ovarian
A2780 cell line and the cisplatin-resistant A2780-Rab25
cell line. Determination of the in vitro cytotoxicity was
performed by MTT assays. No significant difference in
cytotoxicity between free cisplatin and cisplatin@CB[7] was
observed in either cell line (Table 1). These results are
encouraging as encapsulation of cisplatin can lead to large
or complete loss of in vitro cytotoxicity. Recently, we have
shown that cisplatin@CB[7] is just as effective on A2780
s.c. tumours compared with free cisplatin, and in the
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Fig. 2 Rab25 expression increases cisplatin resistance of the human ovarian cancer cell line A2780. a Cell extracts were analysed by Western
Blot to verify the expression of Rab25 after selection with geneticin. Tubulin expression was used as loading control. b The in vitro cytotoxicity
of cisplatin was compared in the empty-vector expressing A2780 and Rab25-expressing A2780 by MTT assay. IC50 is defined as the concentration
of drug required to inhibition of cell growth by 50 %. c and d The in vivo cytotoxicity of cisplatin was analysed for seven days by caliper measurements
in either A2780 (c) or A2780-Rab25 (d) s.c. xenografts following a single dose of cisplatin at its maximal tolerated dose (6 mg/Kg). e Graphical
representation of relative doubling time of A2780 and A2780-Rab25 s.c. xenografts depicting time required for cisplatin-treated xenografts to reach
same size as control. p<0.05, calculated by t-test
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cisplatin-resistant A2780/cp70 tumours CB[7]-encapsulated
cisplatin markedly slows tumour growth. The ability of cis-
platin@CB[7] to overcome resistance in vivo appears to be
a pharmacokinetic effect [21].
We then analysed the in vivo cytotoxicity of cispla-
tin@CB[7] using the A2780-Rab25 i.p. xenografts by bio-
luminescence. Once the tumours could be detected, the
mice were treated on day 1 with a single injection of the
MTD of cisplatin (6 mg/kg) or cisplatin@CB[7] at an
equivalent cisplatin dose (34 mg/kg which equates to a
cisplatin dose of 6 mg/kg). This dose was well tolerated by
the mice, as indicated by their stable body weights over
fourteen days (Fig. 4b). The mice were monitored by
bioluminescence on day zero, three, six and thirteen
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Fig. 3 Comparison between cisplatin treatment in s.c. and i.p. xenografts. a A2780-Rab25 cells were injected at 2 × 106 subcutaneously (s.c.) or
(b) 5 × 106 intraperitoneally (i.p.) in nude mice. Mice were left for approx. 1 weeks (s.c.) or 3–4 weeks (i.p.) to allow tumours to develop. Cisplatin
(6 mg/kg, Cisplatin) was injected s.c. on day 1. Luciferase signal was monitored over time beginning day 0. SEM bars are shown. c Luminescent
signal (arbitrary units) at day 14 compared to their relative luminescent starting signal at day zero. d In vitro increase in endogenous p53
expression following treatment of cells with 1uM cisplatin. e Overnight culture of cells on 24 well plates was incubated for 24 hours with cisplatin
(4 wells per concentration). Luciferase activity was measured using the Xenogen IVIS and the cells counted. Luciferase activity is expressed as total
flux × 103 per 1000 cells. f Mice (12) were injected i.p. with 5 × 106 A2780Rab25p53-Luc cells. Tumours developed over 27 days. The mice were
imaged before and 24 hours after treatment with cisplatin 6 mg/Kg i.p. (6 mice in each group). Representative example of bioluminescent
imaging signal. Graph depicts relative increase in p53 response luminescent signal
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after treatment injections. Tumours in the control
group increased in luminescent signal by 17.1 fold
compared to their relative luminescent starting signal
at day zero (Fig. 4a). Conversely, both free cisplatin and
cisplatin@CB[7] displayed a significant ability to retard
tumour growth (Fig. 4a). As previously shown, the signal
of the cisplatin treated tumours was 48.8 ± 21 % less than
that of the vehicle cohort (Ctl) at the last time point. cis-
platin@CB[7] tumour growth retardation was significantly
more pronounced than free cisplatin; presenting an 84.4 ±
5 % reduction in signal to that of control mice at the last
time point. To verify that the effect observed by
Table 1 Comparison between cisplatin and cisplatin@CB[7]
toxicty by MTT assay. The in vitro cytotoxicity of cisplatin and
cisplatin@CB[7] in the human ovarian cancer cell line A2780 and
its cisplatin-resistant cell line A2780-Rab25. IC50 is defined as the
concentration of drug required to inhibition of cell growth by
50 % ovarian cancer cell line A2780 and its cisplatin-resistant cell
line A2780-Rab25. IC50 is defined as the concentration of drug
required to inhibition of cell growth by 50 %
Cell line IC50 (μM) Cisplatin Cisplatin@CB[7]
A2780 0.16 ± 0.01 0.16 ± 0.001
A2780-Rab25 0.47 ± 0.04 0.42 ± 0.02
BA
Control Cisplatin
Cisplatin @CB[7]
i.p. 
Cisplatin@CB[7]
s.c. 
C
E
N
N
NT
T
T
T
Ctl
Cisplatin i.p.
Cisplatin s.c.
Time (days)
R
el
at
iv
e 
tu
m
ou
r 
vo
lu
m
e
0 2 4 6 8
0
2
4
6
1
5
3
D
Ctl
Cisplatin i.p.
Cisplatin s.c.
Time (days)
0 2 4 6 8
0
0.4
0.8
1.2
1.0
0.6
R
el
at
iv
e 
w
ei
gh
t (
g)
0.2
Time (days)
0 2 4 6 8 10 12 14 16
0
2
4
6
8
10
12
14
16
18
20
Ctl 
Cisplatin 
CB7-Cisplatin i.p. 
CB7-Cisplatin s.c. 
tl
isplat
isplatin@CB[7] i.p.
isplatin@CB[7] s.c.
R
el
at
iv
e 
w
ei
gh
t (
g)
Time (days)
F
lu
x 
(F
ol
d 
v 
D
ay
 0
)
**
**
**
A2780-Rab25
Intraperitoneal Xenograft
Time (days)
0 2 4 6 8 10 12 14 16
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Ctl 
CDDP 
CB7-CDDP i.p. 
CB7-CDDP s.c. 
tl
isplatin
isplatin@CB[7] i.p.
isplatin@CB[7] s.c.
Ti e ( s)
A2780-Rab25
Intraperitoneal Xenograft
Fig. 4 Cisplatin@CB[7] retains its enhanced activity in the disseminated ovarian cancer model. a Delay on intraperitoneal tumour growth over
14 days of A2780-Rab25 i.p. xenografts following injection on day 1 of saline (Ctl), cisplatin at 6 mg/kg, cisplatin@CB[7] at 34 mg/kg (equivalent to
6 mg/kg of cisplatin), and subcubtaneous injection of cisplatin@CB[7] at 34 mg/kg (equivalent to 6 mg/kg of cisplatin). SEM bars are shown. b
Relative body weights over fourteen days after treatment. c Comparison between cisplatin treatment injected through s.c. or i.p. route in A2780
subcutaneous xenografts measured for tumour volume by calipers after cisplatin injection on day 0. Body weight was monitored for the duration
of the experiment. SEM bars are shown. d Relative body weights over fourteen days after treatment. e Representatitve H&E images of orthotopic
ovarian tumours (T) from the control, cisplatin, cisplatin@CB[7] injected i.p. and cisplatin@CB[7] injected s.c. cohorts. Necrotic regions (N) are
observed in all cisplatin cohorts
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cisplatin@CB[7] on the growth of tumours was independ-
ent to the route of administration, a fourth group of mice
bearing i.p. A2780-Rab25 tumours was injected subcutane-
ously with cisplatin@CB[7]. The signal of the s.c. cispla-
tin@CB[7] treated mice was slightly higher than that of i.p.
cisplatin@CB[7], with a signal of 29.3 ± 16 % to that of the
control mice at day 14. This result correlates with our pre-
vious validation for cisplatin treatment where injection via
i.p. or s.c. route gives a very similar response to tumour
growth retardation compared to the control mice (Fig. 4c).
No changes in relative body weight all cohorts (vehicle or
cisplatin/cisplatin@CB[7] cohorts) demonstrated that this
novel compound is well tolerated by mice (Fig. 4b).
Pathology of the disseminated disease following cisplatin
and CB[7]-cisplatin treatment
The disease observed in the control group had different
characteristics compared to that of the treatments groups.
The control group was characterised by disseminated dis-
ease with widespread small tumours growing in the periton-
eum and the occasional appearance of one or two medium
size tumours attached to organs (6 out of 6 mice, Table 2).
Conversely, both free cisplatin and cisplatin@CB[7] pre-
sented little disseminated disease. Instead, the presence
of one or two very big tumours attached to organs was
observed. The tumours were extracted, formalin-fixed,
paraffin-embedded and analyzed by hematoxylin and eosin
stain. Examination of the tumours showed extensive areas
of necrosis in the tumours from the treated mice, present-
ing larger necrotic areas in the cisplatin@CB[7] group
compared to the free cisplatin group (Table 2 and Fig. 4e),
confirming its enhanced activity.
Discussion
Ovarian cancer commonly presents at a late stage with ex-
tensive metastatic deposits in the peritoneum and abdomi-
nopelvic organs. In order to properly evaluate novel
therapies and delivery systems for this type of disease, pre-
clinical models that recapitulate better the human presen-
tation are essential. Rab25 expression in ovarian cancer
cell lines results in a more invasive phenotype in vitro and
in vivo, with extensive metastatic deposits in the periton-
eum and abdominopelvic organs [16] and Fig. 2). Here, we
show a modest increased cisplatin resistance induced by
Rab25 expression in the ovarian cancer cell line A2780 in
vitro. This modest increase parallels observations in the
clinic, where resistance can be gained by just a small order
of magnitude. Induction of cisplatin-resistance via overex-
pression of Rab25 in the ovarian cancer cell line SKOV-3
has also been recently reported. Our results expand our
understanding of cisplatin resistance, where resistance to
treatment also depends on the microenvironment, as dem-
onstrated by the increased cisplatin resistance of the i.p.
tumours compared to no changes in sensitivity in a sub-
cutaneous model. For the past two decades, s.c. xenografts
have constituted the major pre-clinical screen for the de-
velopment of novel cancer therapeutics. Despite limita-
tions, these models have identified clinically efficacious
agents, and remain the ‘workhorse’ of the pharmaceutical
industry. However, they have received criticism as good
animal models for pre-clinical drug evaluation as they lack
the proper microenvironment which might determine
therapeutic response [22]. Our results clearly demonstrate
the role that the microenvironment plays on therapeutic
response, exemplifying further why we require models that
recapitulate the human presentation.
Another disadvantage of the s.c. models are the way that
these tumours are monitored. Caliper measurements are
error-prone due to variability in tumour shape, skin thick-
ness and subcutaneous fat layer thickness. Observer sub-
jectivity and differences in the compressibility of the
tumour can also easily lead to increased errors [23]. In
addition, some subcutaneous xenografts are known to de-
velop necrotic centres, giving an underestimated value of
drug effect [24]. With the advent of non-invasive visible
light imaging technology, biological processes such as
tumour load can be monitored in live animals through time,
without restriction in their localisation. Because of its sensi-
tivity, luminescence also allows to initiate drug evaluation
much earlier than with calipers, which permits analysis of
tumour growth for longer periods of time. Our data illus-
trates that bioluminescence quantification is a reliable
method to monitor tumour burden allowing for direct com-
parison between a disseminated model and the s.c. model
and demonstrates that the microenvironment determines
tumour therapeutic response. Furthermore, using this
Table 2 Peritoneal Disease observed after cisplatin or cisplatin@CB[7] treatment. Pathological observations of the i.p. tumours
extracted from the control, cisplatin and cisplatin@CB[7] groups. Size of tumour was determined as follows: + < 0.5 cm; ++ >0.5 cm
< 1 cm; +++ >1 cm in diameter. Dissem. D. = Disseminated disease was determined as >3 small tumours spreaded throughout the
peritoneal cavity
Treatment Dissem. Disease Attached to organ Size of Tumours Tumour for H&E % of Necrotic Area
Control 6/6 4/6 + 3/6 11.66 ± 8.924 %
Cisplatin i.p. 3/6 3/6 ++ 4/6 32 ± 6.75 %
Cisplatin@CB[7) i.p. 2/6 4/6 +++ 6/6 47.85 ± 10.11 %
Cisplatin@CB[7) s.c. 0/5 5/5 +++ 4/5 47.5 ± 18.35 %
Gomez-Roman et al. Journal of Ovarian Research  (2015) 8:62 Page 7 of 10
system we have been able to identify the therapeutic benefit
of a novel cisplatin drug delivery system. These results sug-
gest that the establishment and growth of s.c. xenografts
differs from that of xenografts in the peritoneal cavity.
Our results might explain the poor clinical performance
observed of novel cancer drugs in the clinic which have
been previously evaluated in unsuitable pre-clinical models.
Conclusions
Continued advancement in cancer research depends on
the use of adequate experimental animal models in order
to develop appropriate therapies that will translate better
into the clinic. Our data indicate that the bioluminescent
i.p. model resembles the clinical outset and might im-
prove pre-clinical screening. We also confirm increased
anti-tumour activity of the novel cisplatin@CB[7] com-
pared to free cisplatin in the i.p. model. Our results
demonstrate that cisplatin@CB[7] may have utility in the
treatment of drug-resistant ovarian human cancers and
warrant further investigation.
Methods
Materials
Cisplatin, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide] were obtained from Sigma-
Aldrich Co. Ltd (Dorset, UK). Luciferin was obtained
from Caliper Lifesciences Ltd (Wellfield, UK). G418S
Sulphate solution was obtained from ForMedium Ltd
(UK). Blasticidin, Lipofectamine 2000, Virapower Pro-
moterless Lentiviral Gateway Kit were obtained from
Invitrogen Co. (Paisley, UK).
Preparation of cisplatin@CB[7]
Cisplatin (Sigma-Aldrich) and CB[7] were stirred together
in hot water until dissolved, then stirred for a further 3 h
before being either freeze dried or rotary evaporated to
dryness. The water content of the cisplatin@CB[7] com-
plex was then determined by elemental analysis and found
to be between 5 and 13 water molecules per batch. These
waters of crystallisation were taken into account when
calculating the molecular mass of cisplatin@CB[7] and
the subsequent concentrations of each batch in solution
before administration.
Luciferase reporters
Two luciferase lentiviral constructs were produced
(pLenti-UbCp-Luc and pLenti-p53 RE-Luc) using the
ViraPower Promoterless Lentiviral Gateway Expression
System according to manufacturers’ instructions for the
generation of stable cell lines expressing luciferase under
the control of the Ubiquitin C promoter or a p53 re-
porter containing p53 binding regions. For the Ubiquitin
C-Luciferase lentiviral construct, the pENTR™5’-UbCp
plasmid containing the Ubiquitin C promoter (supplied
in the kit) and the pENTR™/D-TOPO®-Luciferase plas-
mids were combined with the promoterless pLenti6/
R4R2/V5-DEST destination vector (Invitrogen, cat. No.
K5910-00) into which the promoter and gene of interest
were transferred using MultiSite Gateway® Technology
(no ligase, post-PCR procedures or restriction enzymes
required). The luciferase gene was amplified from plas-
mid pGL4-CMVLuc (Promega) using the following
primers: Forward-5′ CACCATGGAAGACGCCAAA;
Reverse-5′ AAACACGGCGATCTTTCCG and cloned
into the pENTR™ Directional TOPO® plasmid (Invitro-
gen, cat. No. K2400-20). For the p53-Luciferase lentiviral
construct, the p53 binding region was amplified from
the p53 Luciferase Reporter Vector (Panomics, cat. No
LR0057) using the following primers: Forward-5′
GGTACCGAGCTCTTA; Reverse-5′ GCT TTACCAA-
CAC. The PCR product was cloned into pENTR 5′-
TOPO TA plasmid (Invitrogen, cat. No. K591-10). The
pENTR™5′TOPO®TA plasmid containing the p53 bind-
ing region (pENTR™5′TOPO®TA-p53RE) and the
pENTR™/D-TOPO®-Luciferase plasmid were combined
with the promoterless pLenti6/R4R2/V5-DEST destin-
ation vector (Invitrogen, cat. No. K5910-00) into which
the promoter and gene of interest were transferred using
MultiSite Gateway® Technology (no ligase, post-PCR
procedures or restriction enzymes required) and lenti-
viral construct was produced through recombination.
All PCR reactions were carried out with Proofstart DNA
Polymerase (Qiagen) following manufacturer’s protocols.
Cloning of the luciferase product into pENTR™-gene and
of the p53 reporter into pENTR™-TOPO®TA was done ac-
cording to manufacturers’ instruction (Virapower™ Promo-
terless Lentiviral Gateway® Kits). Cloning product was
confirmed by sequencing with ABI PRISM 3130XL Gen-
etic Analyzer (Applied Biosystems, Foster City, CA). For
lentivirus production, transfection 3 μg of either pLenti-
UbiquitinCpromoter-Luciferase and pLenti-p53 reporter-
Luciferase constructs plus ViraPower™ Packaging Mix was
performed following manufacturer’s instructions (Invitro-
gen cat. No. K5910-00). Viruses (lentivirus-p53RE-Luc or
lentivirus-UbCp-Luc) were harvested 72 hr post transfec-
tion, filtered through 0.45 μm filter (Millipore, Bedford,
MA) and re-suspended in fresh medium or array buffer.
Titers of lentiviral preparations were determined using
A2780 cells and were around 106 IFU/ml. To infect cells
using lentiviral vectors, cells were placed in a 6-well plate
at a density of 5x107 million cells/well the day before in-
fection. The next day medium was removed and 2 ml
lentivirus in cell culture medium was added in the pres-
ence of 2 μg/ml polybrene to initiate infection. Viruses
were removed 24 hr after infection and fresh cell culture
medium was added. After 24 hr, blasticidin (2.5 μg/ml)
was added and selection performed for cells expressing
luciferase.
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Cell lines
The human ovarian carcinoma cell line A2780 was ob-
tained from Dr. R. F. Ozols (Fox Chase Cancer Centre,
Pennsylvania, U.S.A.). Cells were maintained in Roswell
Park Memorial Institute 1640 medium (Invitrogen) con-
taining glutamine (2 mM) and foetal calf serum (10 %).
The stable cell lines expressing Rab25 or empty vector
were generated by selection of transfected cells with
pcDNA3-Rab25 or pcDNA3 plasmid using Lipofectamine
2000 according to manufacturers’ instructions. Once sta-
bles cells were selected and analysed for Rab25 expression,
they were transduced with a firefly luciferase reporter pre-
viously generated and clones were selected with blastici-
din. Stable cell lines expressing Rab25 and luciferase were
grown in the presence of geneticin (0.5 mg/ml) and blasti-
cidin (2.5 μg/ml ). Cells were grown in the absence of
drugs for 24 hours before in vivo experiments and for the
duration of experiment for in vitro assays.
Cytotoxicity assay
Drug sensitivity was determined by tetrazolium based
chemosensitivity assay as described previously [25].
Briefly, cells were plated out at a density of 1x103 per
well in 96-well flat bottomed plates (IWAKI) and
allowed to attach and grow for 2–3 days. They were ex-
posed to cisplatin for 24 hr and fresh media was added
on the following day. On the fourth day after treatment,
MTT (50 μL, 5 mg/mL) was added to each well. Plates
were incubated in the dark at 37 °C for 4 hr, media and
MTT removed and the MTT-formazan crystals dissolved
in dimethyl sulphoxide (200 μL/well). Glycine buffer
(25 μL/well, 0.1 M, pH 10.5) was added and the absorb-
ance measured at 570 nm in a multi-well plate reader
(Model Emax, Molecular Devices Ltd., Wokingham UK).
Results are expressed in terms of the drug concentra-
tion required to kill 50 % of the cells (IC50) estimated as
the absorbance value equal to 50 % of that of the control
untreated wells.
Tumour growth delay in vivo
Cell lines A2780 and A2780-Rab25 were established as
xenografts in six to eight-week-old athymic female nude
(MF1 nu/nu) mice. Monolayer cultures were harvested
with trypsin/EDTA and resuspended in PBS. Animals
were housed in autoclaved microisolator cages in an air-
filtered laminar flow cabinet and were given food and
water ad libitum. All procedures were performed under
sterile conditions in a laminar flow hood.
Ethical approval
Animal experiments were in compliance with all regula-
tory guidelines, as described in the Animals Act 1986
Scientific Procedures on living animals regulated by the
Home Office in the United Kingdom.
For xenografts studies, 2x106 cells were injected into
the right flank of mice for the s.c. model and 5 × 106
cells were injected in the peritoneal cavity for the i.p.
model [16]. Two weeks later, tumour bearing mice were
randomized into groups of six and tumour volume and
body weight recorded daily for duration of experiment.
Mice were injected i.p. with the maximum tolerated dose
of cisplatin (6 mg/Kg) on day 1. Tumour volumes were
estimated by caliper measurements assuming spherical
geometry (volume = π/6xd3, where d is the mean diam-
eter). For luminescence recording, mice were injected
s.c. with 200 μl of the D-luciferin substrate (30 mg/ml).
Following injection, mice were anaesthetised with iso-
flurane (3 % and 1 liter/min oxygen) and placed in the
imaging system. Luminescence was recorded 10 min
after luciferin injection with an exposure time of 1 min
using the Xenogen IVIS50 imaging system from Caliper
Life Sciences Ltd. (Wellfield, UK). Imaging was repeated
weekly to allow estimation of tumour burden over time.
For i.p. xenografts, about 5x106 cells were injected into
the peritoneal cavity of mice and mice were imaged on a
weekly basis.
Analysis of the bioluminescent images was performed
by defining a set region of interest to be used in all ani-
mals. For the disseminated model, the signal over the
entire abdomen of the mouse was analysed.
Statistical analysis
Experiment results obtained were statistically evaluated
by simple t-test. Differences were considered significant
if P < 0.05. Statistical analysis was performed by Sigma-
Plot 10.0.
Abbreviations
s.c: Subcutaneous; i.p: Intraperitoneal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NGR carried out animal work, stable cell lines, statistical analysis, participated
in the design and coordination and helped draft the manuscript. FMG
participated in p53 plasmid preparation, stable cell lines and acquisition of
p53 animal data. NJW designed cisplatin@CB[7]. JP helped with the design,
and interpretation of data, and provided help drafting the manuscript. All
authors read and approved the manuscript.
Financial support
The work presented in this manuscript was sponsored by Cancer Research
UK.
Acknowledgements
This work was supported by Cancer Research United Kingdom. We thank
Prof. Jim Norman for supplying the Rab25 vector, and Colin Nixon and
Alyson Sim for histology help.
Author details
1Institute of Cancer Sciences, Wolfson Wohl Translational Cancer Research
Centre, University of Glasgow, Bearsden, Garscube Estate, Glasgow G61 1QH,
Scotland, UK. 2Faculty of Pharmacy, The University of Sydney, Sydney, NSW
2006, Australia.
Gomez-Roman et al. Journal of Ovarian Research  (2015) 8:62 Page 9 of 10
Received: 29 May 2015 Accepted: 4 September 2015
References
1. Pal T, Permuth-Wey J, Sellers TA. A review of the clinical relevance of
mismatch-repair deficiency in ovarian cancer. Cancer. 2008;113(4):733–42.
doi:10.1002/Cncr.23601.
2. Alberts DS, Liu PY, Hannigan EV, OToole R, Williams SD, Young JA, et al.
Phase III study of intraperitoneal cisplatin-intravenous cyclophosphamide
versus intravenous cisplatin-intravenous cyclophosphamide in patients with
optimal disease stage III ovarian cancer: A SWOG-GOG-ECOG Intergroup
study. Int J Gynecol Cancer. 1996;6:28–9.
3. Ledermann JA, Kristeleit RS. Optimal treatment for relapsing ovarian cancer.
Ann Oncol. 2010;21:218–22. doi:10.1093/annonc/mdq377.
4. Bookman MA. The addition of new drugs to standard therapy in the
first-line treatment of ovarian cancer. Ann Oncol. 2010;21:211–7.
doi:10.1093/annonc/mdq368.
5. Parmar MKB, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen
GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional
platinum-based chemotherapy in women with relapsed ovarian cancer: the
ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099–106.
6. Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: A
review, with a focus on practical aspects of treatment. J Clin Oncol.
2006;24(6):988–94. doi:10.1200/Jco.2005.05.2456.
7. Schorge JO, Modesitt SC, Coleman RL, Cohn DE, Kauff ND, Duska LR, et al.
SGO white paper on ovarian cancer: etiology, screening and surveillance.
Gynecol Oncol. 2010;119(1):7–17.
doi:10.1016/j.ygyno.2010.06.003.
8. Lim MC, Song YJ, Seo SS, Yoo CW, Kang S, Park SY. Residual cancer stem
cells after interval cytoreductive surgery following neoadjuvant
chemotherapy could result in poor treatment outcomes for ovarian cancer.
Onkologie. 2010;33(6):324–30. doi:10.1159/000313823.
9. Scott KA, Holdsworth H, Balkwill FR, Dias S. Exploiting changes in the
tumour microenvironment with sequential cytokine and matrix
metalloprotease inhibitor treatment in a murine breast cancer model. Brit J
Cancer. 2000;83(11):1538–43.
10. Al-Niaimi A, Manuelli B, Safdar N, Chappell R, Seo S, Kushner D et al. Survival
with surgical versus medical treatment of patients with bowel obstruction
secondary to ovarian cancer recurrence: A 15-year experience. J Clin Oncol.
2009;27(15).
11. Connolly DC, Hensley HH. Xenograft and transgenic mouse models of
epithelial ovarian cancer and Non invasive imaging modalities to monitor
ovarian tumor growth in situ -applications in evaluating novel therapeutic
agents. Curr Protoc Pharmacol. 2009;45:14 2 1–2 26.
12. Vanderhyden BC, Shaw TJ, Ethier JF. Animal models of ovarian cancer.
Reprod Biol Endocrinol. 2003;1:67. doi:10.1186/1477-7827-1-67.
13. Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ, et al.
Magnetic resonance imaging for detection and determination of tumor
volume in a genetically engineered mouse model of ovarian cancer. Cancer
Biol Ther. 2007;6(11):1717–25.
14. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role
of K-ras and Pten in the development of mouse models of
endometriosis and endometrioid ovarian cancer. Nat Med.
2005;11(1):63–70. doi:10.1038/Nm1173.
15. Ingersoll SB, Yue P, Ahmad S, Turkson J, Edwards JR, Holloway RW.
Molecular characterization of highly tumorigenic cell lines used in a
xenograph model to investigate cellular therapy for the treatment of
refractory ovarian cancer. J Clin Oncol. 2009;27(15).
16. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, et al. The
RAB25 small GTPase determines aggressiveness of ovarian and breast
cancers. Nat Med. 2004;10(11):1251–6. doi:10.1038/Nm1125.
17. Reed E, Yuspa SH, Zwelling LA, Ozols RF, Poirier MC. Quantitation of
Cis-Diamminedichloroplatinum-Ii (Cisplatin)-DNA-intrastrand adducts in
testicular and ovarian-cancer patients receiving cisplatin chemotherapy.
J Clin Invest. 1986;77(2):545–50.
18. Lagona J, Fettinger JC, Isaacs L. Cucurbit[n]uril analogues: synthetic and
mechanistic studies. J Org Chem. 2005;70(25):10381–92.
doi:10.1021/Jo0516655r.
19. Kim J, Jung IS, Kim SY, Lee E, Kang JK, Sakamoto S, et al. New cucurbituril
homologues: syntheses, isolation, characterization, and X-ray crystal
structures of cucurbit[n]uril (n = 5, 7, and 8). J Am Chem Soc.
2000;122(3):540–1.
20. Kim J, Ahn Y, Park KM, Kim Y, Ko YH, Oh DH, et al. Carbohydrate wheels:
cucurbituril-based carbohydrate clusters. Angew Chem Int Ed Engl.
2007;46(39):7393–5. doi:10.1002/anie.200702540.
21. Plumb JA, Venugopal B, Oun R, Gomez-Roman N, Kawazoe Y,
Venkataramanan NS, et al. Cucurbit[7]uril encapsulated cisplatin
overcomes cisplatin resistance via a pharmacokinetic effect. Metallomics.
2012;4(6):561–7. doi:10.1039/c2mt20054f.
22. Morton CL, Houghton PJ. Establishment of human tumor xenografts in
immunodeficient mice. Nat Protoc. 2007;2(2):247–50.
23. Jensen MM, Jorgensen JT, Binderup T, Kjaer A. Tumor volume in
subcutaneous mouse xenografts measured by microCT is more accurate
and reproducible than determined by 18 F-FDG-microPET or external
caliper. BMC Med Imaging. 2008;8:16.
24. Black PC, Shetty A, Brown GA, Esparza-Coss E, Metwalli AR, Agarwal PK, et al.
Validating bladder cancer xenograft bioluminescence with magnetic
resonance imaging: the significance of hypoxia and necrosis. BJU Int.
2010;106(11):1799–804.
25. Plumb JA, Milroy R, Kaye SB. Optimization of a chemosensitivity assay based
on reduction of the tetrazolium Dye, Mtt. Anticancer Res. 1987;7(5):902.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gomez-Roman et al. Journal of Ovarian Research  (2015) 8:62 Page 10 of 10
